GrodskyJDSchehleinEMChangDF, et al. So many injections, so much waste: understanding the environmental impact of intravitreal injections. J Vitreoretin Dis. 2025;9(2):131-134.
2.
El-AliOKoklanisKVukicevicMHeriotWJ.Postoperative outcomes of combined phacovitrectomy for epiretinal membrane with a concurrent cataract vs standalone phacoemulsification for a cataract. J Vitreoretin Dis. 2025;9(2):135-143.
3.
KannanNBVallinayagamMBalakrishnanTSarkarADRajanRPRamasamyK.Short-term endotamponade with perfluorocarbon liquids for giant retinal tear–associated retinal detachment. J Vitreoretin Dis. 2025;9(2):144-150.
4.
CitirikMIlhanCHorozoglu CeranTTekeMY.Vitrectomy with short-term perfluorocarbon liquid tamponade for retinal detachment with inferior retinal breaks and proliferative vitreoretinopathy. J Vitreoretin Dis. 2025;9(2):151-157.
5.
HeierJSLiuYHolekampNM, et al. Clinical use of home OCT data to manage neovascular age-related macular degeneration. J Vitreoretin Dis. 2025;9(2):158-165.
6.
SzigiatoAMaatoukCMAzarAE, et al. Detection of geographic atrophy guided by optical coherence tomography sub-RPE illumination analysis in patients with intermediate age-related macular degeneration. J Vitreoretin Dis. 2025;9(2):166-173.
7.
KhanMASodhiSKOrrS, et al. Machine learning quantification of fluid volume in eyes with retinal vein occlusion treated with aflibercept: the REVOLT study. J Vitreoretin Dis. 2025;9(2):174-179.
8.
ShethNChangAYBryanJMMassengillMTLimJI.Outcomes of open-globe injuries with associated retinal detachment: experience at an ocular trauma center. J Vitreoretin Dis. 2025;9(2):180-186.
9.
GonzálezNCVillegasVMBerrocalAMGoldASLatiffAMurrayTG.Targeted multimodality treatment to eliminate the need for enucleation in advanced Coats disease. J Vitreoretin Dis. 2025;9(2):187-191.
10.
LaneAMHartleyCDMcCarthyR, et al. Confirmatory cytopathology and potential impact on the predictive value of gene expression profiling in patients with uveal melanoma. J Vitreoretin Dis. 2025;9(2):192-197.
11.
SubramanianBNangiaPRishiP, et al. Clinical profiles of retinal vasoproliferative tumors. J Vitreoretin Dis. 2025;9(2):198-203.
12.
RanaNAChalasaniMMarkleJ, et al. Evaluation of sustained intraocular pressure elevations across antivascular endothelial growth factor agents. J Vitreoretin Dis. 2025;9(2):204-211.
13.
ChalasaniMMaatoukCMarkleJSinghRPTalcottKE.Predictors of vision loss after lapse in antivascular endothelial growth factor treatment in patients with diabetic macular edema. J Vitreoretin Dis. 2025;9(2):212-218.
14.
ParoliniBMatelloVRosales-PadrónJF.Combined surgical approach for repair of refractory macular hole in myopic traction maculopathy. J Vitreoretin Dis. 2025;9(2):219-223.
15.
HabibNBBossJ.Mycophenolate mofetil–induced lymphoproliferative disorder in a young adult with chronic posterior uveitis. J Vitreoretin Dis. 2025;9(2):224-227.
16.
DukeRCTAnshumaliSCrossonJN. Optical coherence tomography angiography in macular neovascularization secondary to focal choroidal excavation. J Vitreoretin Dis. 2025;9(2):228-231.
17.
ShahSda CruzNFSLopez-FontFStaropoliPBerrocalA.Exudative vitreoretinopathy with a Coats-like response in Poretti-Boltshauser syndrome. J Vitreoretin Dis. 2025;9(2):232-235.
18.
YuanMHoyekSKimLAChaayaCPatelN.Antivascular endothelial growth factor injections for the chronic treatment of macula-off, fovea-on diabetic tractional retinal detachment with vitreous hemorrhage. J Vitreoretin Dis. 2025;9(2):236-240.
KimAJSabbaghOSabbaghOAbou-JaoudeMKitchensJW.Tractional retinal detachment in a patient with a history of methamphetamine use. J Vitreoretin Dis. 2025;9(2):257-261.
23.
IftikharMHsuSTVajzovicLHadziahmetovicM.Acute submacular hemorrhage resulting from neovascular age-related macular degeneration in a monocular patient. J Vitreoretin Dis. 2025;9(2):262-265.
